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Long-Term Prostaglandin E1 Therapy in Congenital Heart Defects
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Seventeen neonates received an intravenous infusion of
prostaglandin E. for an average of 39 days (range 8 to
104). Seven (group 1) had transposition of the great
arteries with no ventricular septal defect or a small one;
eight (group 2) had ductus-dependent pulmonary flow
(pulmonary atresia or stenosis in six and tricuspid atresia
in two); and two (group 3) had aortic coarctation, one
with no ventricular septal defect, the other with ven-
tricular septal defect, isthmus hypoplasia and descend-
ing aortic flow supplied mainly by the ductus.
An increase in the arterial partial pressure of oxygen
(Po2) was seen in groups 1and 2. Six patients from group
1 and two from group 2 developed heart failure; cortical
Type E prostaglandins have become a major advance in the
management of neonates with certain critical heart defects
(1-10). Their administration to maintain ductus arteriosus
patency has been, in general, restricted to short periods
(1-8). Although the short-term use in the newborn period
appears to be well established, the experience with the pro-
longed use has been limited and the indications for therapy
unclear (9-17). Our experience with the prolonged infusion
of prostaglandin E, (Upjohn Company) in infants with con-
genital heart defects is presented in this report.
Methods
Patients. The study group comprised the 17 neonates
who were treated with prostaglandin E, for a mean duration
of 39 days (range 8 to 104) at our hospital from September
1979 to April 1983 (Table I). Seven patients (group I) had
transposition of the great arteries and intact ventricular sep-
tum or small septal defect; eight patients (group 2) had
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hyperostosis of long bones was seen in three patients
from group 1 and three from group 2; one from group
1 had refractory diarrhea. Other side effects seen at the
beginning improved as the rate of infusion diminished.
In group 3, the patient with complex coarctation had a
decrease in blood pressure in the arms, an increase in
pressure in the legs and restoration of renal function; in
the patient with no ventricular septal defect, heart fail-
ure worsened during therapy. Histologic changes seen
in three ductus were attributed to the closing process.
When delaying surgery in selected ill infants with
heart defects is deemed advantageous, long-term infu-
sions of prostaglandin E. are feasible.
ductus-dependent pulmonary blood flow (pulmonary atresia
or critical stenosis in six and tricuspid atresia in two); and
two patients (group 3) had aortic coarctation, one with intact
ventricular septum, the other with septal defect, isthmus
hypoplasia and blood flow to the descending aorta supplied
mainly by the ductus arteriosus.
Prostaglandin infusions. The prostaglandin infusion was
maintained whenever it proved beneficial and it was deemed
advantageous to delay surgical therapy beyond neonatal age.
It was discontinued when no hemodynamic improvement
could be proven, when there were persistent side effects
(cortical hyperostosis) or when successful surgery was
accomplished.
Prostaglandin E, was given intravenously at an initial
rate of 0.05j.Lg/kg per min or less, and subsequently de-
creased to the lowest effective dose. In six patients from
group I, the infusion was started after cardiac catheterization
because a satisfactory arterial oxygenation was not achieved
after balloon septostomy; in one patient, the infusion was
started before ballooning. In group 2, prostaglandin E, was
started as soon as ductus-dependent pulmonary blood flow
was suspected, even before confirmatory cardiac catheter-
ization. In group 3, the infusion was started after
catheterization.
Clinical and laboratory data. Arterial blood gases, blood
pressure, temperature, heart rate and respiratory rate deter-
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Table 1. Clinical Summary
Prostaglandin E I Infusion
Age at
Beginning Dose Duration
Patient Diagnosis (days) (flg/kg per min) (days) Complications Surgery Outcome
Group I: Patients With Transposition
TGA,IVS 0.05 19 Heart failurc Blalock-Hanlon at Well at 3 years
3[ days
2 TGA,IVS 0.05 44 Heart failure. Blalock-Hanlon at Mustard procedure
hypotension. 40 days at [I mo
pyrexia. seizure.
diarrhea
3 TGA. small 0.05 X Heart failurc, Senning at 10 mo Well at 3 years
VSD pyrexia
4 TGA,IVS 0.05-0.01 65 Heart failure. Senning at 66 days Died postoperatively
pyrexia. diarrhea. at 66 days
cortical
hyperostosis
5 TGA.IVS 0.05-0.00625 50 Heart failure Blalock-Han[on at Died postoperatively
pyrexia. seizure. 31 days. at 50 days
cortical aortopulmonary
hyperostosis shunt at 50 days
6 TGA. small 6 0.05-0.009 20 Apnea, bradycardia Well at 6 mo
VSD
7 TGA.IVS 0.05-0.015 104 Heart failure, Blalock-Hanlon at Well at 5 mo
pyrexia. cortical 99 days
hyperostosis
Group 2: Patients With Ductus-Dependent Pulmonary Blood Flow
8 LTGA, VSD. 2 0.05 42 Hypotension. rash. Aortopulmonary Died postshunt
P Atr tachycardia, shunt at 44 days revision at 2 mo
tachypnea.
bradycardia
9 P Atr. IVS 3 0.05 [[ Pyrexia, seizure Pulmonary Well at 3 years
valvotomy at 9
days
10 P Atr, IVS, 0.05 14 Heart failure, Pulmonary Died
hypopl RV seizure valvotomy at 14 intraoperatively
days
II T Atr. VSD, 0.05-0.0 [25 20 Pyrexia, tachypnea Aortopu[monary Well at 2 years
hypop[ RV shunt at 7 days
12 P Atr, VSD 0.05-0.0[25 40 Hypotension. seizure Aortopu[monary Well at [ year
shunt at 5, 26 and
40 days
13 ToF 23 0.05-0.02 45 Rash. cortical Aortopulmonary Well at X mo
hyperostosis shunt at 97 days
[4 TGA, T Atr, 0.05-0.0125 35 Tachypnea. Aortopulmonary Died postoperatively
P Atr, VSD tachycardia shunt at 35 days
15 TGA. Mitral 0.05-0.0[25 64 Heart fai[ure. Blalock-Han[on at Well at 4 mo
Atr, SV, pyrexia. apnea. 27 days,
PS bradycardia, aortopu[monary
cortical shunt at 61 days
hyperostosis
Group 3: Patients With Aortic Coarctation
16 Ao coarc. 4 0.017-0.009 3X Tachypnea Ao angioplasty, PA Died postoperatively
VSD. band, PDA
isthmic ligation at 38
hypopl days
17 Ao coarc, IVS [I 0.05 9 Heart fai[ure, Died suddenly at 33
pyrexia, seizurc days
Ao = aortic; Atr = atresia; coarc = coarctation; hypop[ = hypoplasia; IVS = intact ventricular septum: LTGA [evotransposition of the great
arteries: P = pulmonary: PA = pulmonary artery; PDA = patent ductus arteriosus; PS = pulmonary stenosis; RV = right ventricle: SV = single
ventricle; T = tricuspid: ToF = tetralogy of Fallot; TGA = transposition of the great arteries: VSD = ventricular septal defect.
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minations were obtained before the infusion, within I hour
and every 4 hours; blood gases were measured weekly there-
after. Serum glucose and electrolytes, blood urea nitrogen
or creatinine, hemoglobin, hematorcit, white cell and plate-
let counts were monitored at least weekly. Body weight and
urine output were measured daily. Any adverse reaction was
recorded.
Results
Group 1: transposition of great arteries. In these pa-
tients, the arterial partial pressure of oxygen (Po2) increased
from a mean preinfusion level of 27 torr (range 22 to 32)
to a mean postinfusion level of 40 torr (range 31 to 48) that
was elevated for the remainder of the therapy. The efficacy
of prostaglandin E I was tested by occasional interruption of
the infusion followed by a decrease in the arterial oxygen
tension (Fig. I).
Cardiomegaly and cardiac failure developed in six pa-
tients but promptly responded to medical treatment. Sym-
metric cortical hyperostosis of long bones was seen in three
patients after 22, 25 and 84 days, respectively. The patients
were irritable and had tenderness and swelling in the limbs.
Typical radiologic appearance is seen in Figure 2. One pa-
tient had refractory diarrhea requiring total parenteral nu-
trition for 34 days. There were other side effects seen at the
beginning of the treatment similar to those reported previ-
ously (9,18). Seizure-like activity was seen in two patients,
pyrexia in five and hypotension and mild diarrhea in one.
Blalock-Hanlon atrial septectomy was performed in four
patients. In one, the infusion was necessary even after the
septectomy; an aortopulmonary anastomosis was performed
on the 50th day of prostaglandin E, therapy but the child
did not survive surgery. Another patient underwent a mod-
ified Senning procedure on the 66th day of infusion and
died on the first postoperative day. At autopsy, the ductus
was 20 mm long and 9 mm wide; its internal diameter was
6 mm. The midportion had been surgically ligated. Micro-
scopically , fibrinous deposits were seen on the endothelial
surface; the intimal cushions were normal; the internal elas-
tic layer was thin and large interruptions were seen at the
level of the intimal cushions; the media showed clear spaces
consistent with edema and no inner medial necrosis or fibrosis.
Group 2: ductus-dependent pulmonary blood flow. In
these patients a sharp increase in arterial P02 to a mean level
of 48 torr (range 39 to 56) from the pretreatment level of
30 torr (range 22 to 37) was observed (Fig. 3). Adequate
systemic arterial tension was maintained up to 64 days. In
only two patients was cardiac decompensation seen. In two
patients, mild cortical hyperostosis was detected radiolog-
ically on days 39 and 58, respectively. Side effects seen at
the beginning were pyrexia in three patients, hypotension
in two, apnea in one, rash in one, tachypnea in three, tachy-
cardia and bradycardia in two and seizure-like activity in
three.
Two patients (Cases 9 and 10) underwent pulmonary
valvotomy, one dying at surgery. An aortopulmonary shunt
was performed in six patients, two of whom died; the sur-
gery was performed twice in both patients because of throm-
bus formation in the prosthetic tubing. Thrombosis was
immediate in one (Case 14), and delayed in the other (Case
8). At autopsy, in Case 8 the ductus was 20 mm long, 3
mm wide externally and I mm wide internally; the lumen
was covered by fibrinous material; the intimal cushions were
thickened, fibrosed and circumferential; and the elastica was
wavy with focal areas of fragmentation and duplication in
contact with the intimal cushion but there was no interrup-
tion. No fibrosis or necrosis of the inner media or edema
of the outer media was noted.
Group 3: aortic coarctation (Fig. 4). In this group, the
patient (Case 16) with complex coarctation (near arch in-
terruption) had a decrease in blood pressure in the upper
limbs, an increase in blood pressure in the legs and restor-
ation of renal function while the infusion persisted. The
infusion was stopped on the 38th day when subclavian flap
angioplasty, pulmonary artery banding and ductus ligation
were done. In the patient with an intact ventricular septum
(Case 17), heart failure worsened and only cleared when
the prostaglandin infusion was stopped, and marked sys-
temic hypertension unresponsive to medical treatment fol-
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Figure 1. Patient 4. An increase in the
arterial P02 (Pa02) is accompanied by
cardiomegaly and cardiac failure. A de-
crease in POI occurs after occasional in-
terruptions ofthe prostaglandin E, (PGE,)
infusion. Symmetric cortical hyperos-
tosis of long bones of the limbs was seen
on day 22.
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Figure 2. Patient 7. A, Upper limb radi-
ograph on day 98 showing considerable per-
iosteal new bone formation along the hu-
merus, radius and ulna. Similar changes were
seen in the other arm and both lower limbs,
and to a much lesser extent in the clavicles
and ribs. B, Upper limb radiographs 3 months
after prostaglandin E1 therapy had been dis-
continued. Note considerable regression of
the periosteal lesions, equally observed in the
lower limbs.
Figure 3. Patient 10. Adequate arterial P02 (Pa02) is maintained
with prostaglandin E1 infusion (PGE 1).
PGE, (J,Lg/kg/min)
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lowed. He died suddenly 2 weeks after prostaglandin E1
had been discontinued. Postmortem examination revealed a
patent ductus II mm long with an external diameter of 6
mm and an internal diameter of 2 mm. Microscopically, the
intimal cushions were thickened, deformed and fibrosed,
and fibrinous deposits were noted on the surface; the internal
elastic layer was wavy with focal fragmentation and dupli-
Discussion
Morphologic changes in ductus after prolonged pro-
staglandin infusion. The long-term effectiveness of pros-
taglandin E 1 in maintaining ductus patency has been demon-
strated previously (11,12,16,17-21). However, the fear of
adverse effects may restrict its administration to short pe-
riods of time .
Potentially dangerous changes in the structure of the duc-
tus have been attributed to prolonged use of prostaglandin
E\. Cole et al. (17) described the ductus in an infant after
39 days of prostaglandin E\ therapy. It showed disruption
of the internal elastic lamella; localized increase in the me-
dial elastic tissue; areas of disarray and destruction of medial
muscular fibers; medial elastic fragmentation, edema and
cavitation; thickening and mononuclear cell infiltration of
the adventitia at the ductus-pulmonary artery junction, the
infiltration extending to the nerve trunks, which also dis-
played edema and cavitation; and generalized increase of
cation, and areas of interruption were noted in contact with
the intimal cushion; the inner media showed focal necrosis
and fibrosis in continuity with the intimal cushion fibrosis
at the level of the interrupted elastica; and there was edema
of the outer media.
Pulmonary Valvotomy
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Figure 4. Patients 16 (left) and 17 (right).
A decrease in systolic blood pressure (BP)
in the upper limbs and an increase in the
lower limbs is produced by prostaglandin E]
(PGE]) infusion. This relation reverted
whenever the infusion was interrupted.
Changes in urinary output (top left) seen in
Patient 16 correspond to manipulation of the
infusion. Cardiac failure was aggravated in
Patient 17, improving when the therapy was
stopped. R = right.
mucopolysaccharides. Gittenberger-de Groot et al. (22) re-
ported the histologic findings in four ductus after infusion
of prostaglandin E, for 10 hours to 3 days. These consisted
of medial edema and separation by clear spaces, interrup-
tions of the internal elastic lamina and intimal lacerations,
sometimes extending into the media.
In an extensive study to define the normal structure of
the closing ductus, Silver et al. (23) examined 103 speci-
mens from fetuses and newborn infants of different gesta-
tional ages, birth weights and diagnoses, including 17 with
congenital heart defects who received prostaglandin E, over
a period of 4 to 7 days. The lesions found in prostaglandin
E,-treated and nontreated babies consisted of intimal fibrin-
ous deposits, focal hemorrhages and dissecting aneurysms
of differing degrees. Each of these lesions occurred in all
groups with the exception of stillborns, who failed to show
intimal fibrinous deposits or focal hemorrhages, and infants
older than 3 weeks, who did not show dissecting aneurysms.
No morphologic differences could be seen between the three
types of lesions in the prostaglandin E)-treated and non-
treated patients of the same age. The investigators concluded
that the lesions were due not necessarily to the prostaglandin
E, therapy, but to the ductus patency for whatever reason.
In three of our patients, the ductus was examined his-
tologically. The changes found were: I) intimal cushion
thickening and fibrosis in two; 2) internal elastic fragmen-
tation and duplication in two, and interruption in one; and
3) medial edema, necrosis and fibrosis at the cushion level
in two. These changes are also found in the normally closed
ductus (23) and were not attributed to the prostaglandin
therapy. No lacerations, hemorrhage or aneurysms that could
predispose to ductal rupture were found. Similarly, Park et
al. (24) found no significant deleterious morphologic changes
after prostaglandin E, infusion.
Symmetric laminar cortical hyperostosis oflong bones
of the limbs. This adverse effect was seen in five patients,
accompanied by swelling and tenderness in three and de-
tected radiologically only in two. This phenomenon, not
previously reported from North America, has been seen in
Japan in association with long-term infusion of low dose
prostaglandin E, (13,21). These changes in the limbs re-
semble those of Caffey's disease, but the conspicuous ab-
sence of involvement of the mandible, the minimal or no
involvement of the clavicles and the symmetry of the lesions
are in sharp contrast with this disease. Prostaglandins of the
E series are potent local mediators of bone resorption; fur-
thermore, prostaglandin synthesis is necessary for the pro-
duction of osteoclast-activating factor by normal human pe-
ripheral blood leukocytes (25). The stimulation of bone
resorption by the E prostaglandins varies in a bell-shaped
way as the prostaglandin concentration increases (26). As
suggested by Dekel and Francis (27), it is possible that the
same prostaglandin at a higher concentration stimulates bone
formation. Why the local effects are more prevalent in the
long bones of the limbs is uncertain.
Other side effects. These occurred at the beginning of
therapy and lessened when the rate of infusion was de-
creased. These adverse reactions may also occur during
short-term therapy, and have been reported previously else-
where (9-18). Heart failure due to the prolonged added
ductus flow was seen in some of our patients. Although in
patients with transposition or ductus-dependent pulmonary
blood flow, heart failure was easily managed medically or
with a decrease in the prostaglandin E] infusion, in patients
with simple coarctation improvement was only achieved
after the infusion was discontinued.
Conclusions. The ductus responsiveness to prostaglan-
din E) persists for many weeks. Adverse effects are seen
mostly at the beginning of the therapy, are dose-related and
reverse promptly when the treatment is stopped or the dose
is decreased. Symmetric cortical hyperostosis of long bones
may be seen after 3 weeks of therapy. It also appears to be
dose-related, taking longer to manifest when smaller doses
are used. It reverses spontaneously, clinically and radio-
logically, when the treatment is discontinued. Morphologic
changes observed in the ductus are likely related to the
normal closing process, not to the use of prostaglandin.
When it is deemed advantageous to delay surgery in selected
critically ill infants with congenital heart defects, long-term
infusions of prostaglandin E] are feasible.
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